Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database
Background Patients with ZZ (Glu342Lys) α-1-antitrypsin deficiency (ZZ-AATD) who received augmentation therapy with α-1-antitrypsin (AAT) in randomised controlled trials over 2–3 years failed to show a significant reduction of the annual decline of forced expiratory volume in 1 s (FEV1). Methods To...
Main Authors: | Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley, Jan Stolk |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2021-08-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/7/3/00194-2021.full |
Similar Items
-
Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
by: Hiller AM, et al.
Published: (2019-05-01) -
Update on α1-antitrypsin deficiency
by: Ilaria Ferrarotti, et al.
Published: (2018-06-01) -
Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
by: Robert A. Stockley, et al.
Published: (2018-07-01) -
An Analysis of Post Lung Transplant FEV1 Change in Alpha-1 Antitrypsin Deficiency
by: Gildea, Thomas R.
Published: (2010) -
There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
by: Stockley JA, et al.
Published: (2021-03-01)